Latest Breaking News On - Tom equels - Page 1 : comparemela.com

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript

Operator: Hello. And welcome to the AIM ImmunoTech Fiscal Year 2023 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

United statesChristopher mcaleerJason mccarthyJames molloyChris mcaleerTom equelsThomas equelsImmunotech incDelaware supreme courtPriority developmentExchange commissionMaxim groupEarly access programClinical cancer researchUniversity of pittsburghAlliance global partners

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca's Imfinzi for the Treatment of Pancreatic Cancer

OCALA - AIM ImmunoTech Inc. today announced that enrollment is open at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM s Ampligen with AstraZeneca s anti-PD-L1 immune.

United statesThomask equelsTom equelsJenene thomasExchange commissionErasmus medical centerImmunotech incMedical centerCoordinating investigatorExecutive officerBig pharmaResponse evaluation criteriaPrivate securities litigation reform actNews publishing

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer -January 10, 2024 at 08:46 am EST

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla.,.

United statesTom equelsThomask equelsImmunotech incErasmus medical centerExchange commissionCoordinating investigatorExecutive officer thomasBig pharmaResponse evaluation criteriaPrivate securities litigation reform act

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer | 10.01.24

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer | 10.01.24
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesTom equelsThomask equelsErasmus medical centerImmunotech incExchange commissionCoordinating investigatorExecutive officer thomasBig pharmaResponse evaluation criteriaPrivate securities litigation reform act

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change

/PRNewswire/ Ted D. Kellner, Todd Deutsch and Robert L. Chioini (collectively, the "Kellner Group") today issue the following statement in connection with.

New yorkUnited statesNew jerseyWilliam mitchellTom equelsRobertl chioiniStewart appelrouthTedd kellnerNancy bryanTodd deutschKazem kazempourOkapi partnersExchange commissionDamage the companyKellner group is fullyKellner group